Fuchs E J, Seber A, Altomonte V, Braine H G, Humphrey R L, Jones R J, Noga S J, Schepers K, Wright S K, Vogelsang G B
Division of Hematologic Malignancies, Johns Hopkins Oncology Center, Baltimore, MD 21287, USA.
Bone Marrow Transplant. 1998 Aug;22(3):303-5. doi: 10.1038/sj.bmt.1701323.
Two patients with multiple myeloma in relapse after allogeneic BMT received donor lymphocyte infusions (DLI) but later required chemotherapy for treatment of myeloma-related complications. In both patients, recovery from chemotherapy-induced aplasia was accompanied by manifestations of graft-versus-host reactions. The first patient developed grade II acute GVHD and a complete remission which has lasted >22 months. The second patient developed grade III acute GVHD but died with co-existing GVHD and extensive extramedullary myeloma. These results demonstrate that chemotherapy does not nullify the ability of donor lymphocytes to mediate graft-versus-host reactions.
两名异基因骨髓移植后复发的多发性骨髓瘤患者接受了供体淋巴细胞输注（DLI），但后来因骨髓瘤相关并发症需要化疗。在这两名患者中，化疗诱导的再生障碍恢复过程中均伴有移植物抗宿主反应的表现。第一名患者发生了II级急性移植物抗宿主病（GVHD）并获得完全缓解，缓解持续时间超过22个月。第二名患者发生了III级急性GVHD，但死于并存的GVHD和广泛的髓外骨髓瘤。这些结果表明，化疗不会消除供体淋巴细胞介导移植物抗宿主反应的能力。
Zotero 插件